CORRECTION: Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis

The press release published on November 2, 2022, at 08:00 CET, incorrectly stated November 16, 2022, as the last day of trading in warrants of series TO 1. The last day of trading in warrants of series TO 1 is November 14, 2022.

The full press release, updated to reflect the correct date, follows below.

Oslo, Norway, November 2, 2022 - On November 2, 2022, the exercise period for the warrants of series TO 1 issued in connection with Genetic Analysis AS's ("GA" or the "Company") IPO in September/October 2021 will commence. The exercise period runs until 16 November 2022. Holders of series TO 1 warrants are entitled to subscribe for one new share in the Company for each warrant at a price of NOK 9.30 per share - the closing price of GA's share as of 31 October was NOK 1.85 per share, which is significantly lower than the subscription price and thus something that option holders should be aware of when considering possible subscription of shares.

Ronny Hermansen, CEO Genetic Analysis, comments:

"In connection with GA's listing, warrants of series TO 1 were issued, with exercise period during November 2-16, 2022. During this year's uncertain stock market climate, biotech companies have generally seen a negative share price performance during 2022. Any proceeds from TO 1 was intended to be invested in the development of new markers for our GA-map platform. Given this situation, GA will be agile and continue to focus on the commercialisation of our current products, in which the market has shown strong interest with several significant collaboration agreements signed in recent months."

More information on warrants of series TO 1

In connection with the Company's issue of units prior to the listing on Spotlight Stock Market during September/October 2021, in addition to 7,700,000 shares, 4,620,000 warrants of series TO 1 were issued consideration-free and are listed on the Spotlight Stock Market and registered in Euronext VPS Norway. General terms and conditions and information on the TO 1 warrants are set out below:

• The subscription price is NOK 9.30 per new share. Through the exercise of warrants of series TO 1, GA can raise a maximum total of approximately NOK 43 million before issue costs.
• Subscription of new shares based on warrants of series TO 1 will take place during the period 2–16 November 2022.
• Subscription notification shall be made directly to the Company by completing, signing and sending to the Company no later than November 16, 2022. The document is available on the Company's website https://www.genetic-analysis.com/ipo-2021/. The subscription amount shall be paid in NOK to the Company's bank account within two days.
• The last trading day for warrants of series TO 1 is November 14, 2022.
• Communication of the outcome is expected to take place on or about November 21, 2022.
• No interim shares will be issued.
• The Company's Series TO 1 warrants are traded on the Spotlight Stock Market under the short name GEAN TO 1 and ISIN code NO0011054223.

Advisers and issuing agents

Sedermera Corporate Finance AB is the Swedish financial advisor to GA in connection with the exercise of warrants of series TO 1. The law firm Wiersholm AS is acting as legal advisor and DNB Bank ASA is acting as issuing agent. Shark Communication AB is advising the Company on communications.

This is a translation of the Swedish original. If there is any inconsistency between the English and Swedish versions, the Swedish version shall prevail.

For more information about warrants of series TO 1, please contact:
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com

For more information about GA, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com